A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.

NCT Number	NCT07556549
Lead Sponsor	Pfizer
Conditions	Non-Small Cell Lung Cancer ALK-positive
Enrollment	50 participants
Start Date	2026-05-18
Primary Completion	2026-08-30 (estimated)
Study Completion	2026-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-10